SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals filed an amended 8-K to correct a scrivener's…

CATALYST PHARMACEUTICALS, INC. · 8-K/A filed Mar 19, 2026 at 06:03 ET

At the news

NEUTRALIMPACT 4/10

8-K/A filed Mar 19, 2026 at 06:03 ET

Catalyst Pharmaceuticals filed an amended 8-K to correct a scrivener's error in the signature date of a prior filing. The amendment confirms a court order delaying the bench trial with Hetero USA, Inc. over FIRDAPSE patent validity from March 23, 2026 to May 18, 2026. No other changes were made.

  • Amendment No. 1 to Form 8-K filed to correct a scrivener's error in the signature date of the original March 18, 2026 filing.
  • District Court for the District of New Jersey delayed the bench trial in the patent litigation with Hetero USA, Inc. from March 23, 2026 to May 18, 2026.
  • The litigation concerns the validity of Catalyst's Orange Book-listed patents for FIRDAPSE, which expire in 2032, 2034, and 2037.
  • No other changes were made to the original filing; the delay does not reflect a ruling on the merits of the case.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access